Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

Breast Cancer Research

Table 2 Changes in H -score in pHER2, pERK1 and pAKT

Patientnumber	pHER2 expression						pERK1 expression						pAKt expression
	Pre-lapatinib			Post-lapatinib			Pre-lapatinib			Post-lapatinib			Pre-lapatinib			Post-lapatinib
	Intensity	Percentage	H-score	Intensity	Percentage	H-score	Intensity	Percentage	H-score	Intensity	Percentage	H-score	Intensity	Percentage	H-score	Intensity	Percentage	H-score
1	N/A	N/A	N/A	2+	90%	180	3+	26%	78	1+	46%	46	1+	5%	5	1+	40%	40
2	3+	91%	273	3+	90%	270	3+	77+	231	2+	76%	152	1+	80%	80	2+	95%	190
3	3+	90%	270	2+	43%	86	2+	80%	160	1+	2%	2	2+	50%	100	3+	3+	285
4	3+	90%	270	1+	77%	77	1+	10%	10	1+	30%	30	2+	95%	190	2+	95%	190
5	3+	90%	270	N/A	N/A	N/A	1+	10%	10	N/A	N/A	N/A	3+	90%	270	N/A	N/A	N/A
6	N/A	N/A	N/A	3+	90%	270	N/A	N/A	N/A	2+	10%	20	N/A	N/A	N/A	1+	95%	95
7	2+	47%	94	1+	5%	5	1+	20%	20	1+	8%	8	2+	90%	180	1+	95%	95
8	3+	90%	270	N/A	N/A	N/A	0	0	0	0	0	0	2+	95%	190	N/A	N/A	N/A
9	3+	90%	270	0	0	0	1+	80%	80	0	0	0	1+	90%	90	1+	90%	90
10	3+	50%	150	0	0	0	1+	90%	90	0	0	0	3+	90%	270	1+	95%	95
11	3+	73%	219	N/A	N/A	N/A	1+	10%	10	N/A	N/A	N/A	3+	90%	270	N/A	N/A	N/A
12	N/A	N/A	N/A	1+	5%	5	0	0	0	0	0	0	0	0	0	0	0	0
13	2+	90%	180	N/A	N/A	N/A	1+	10%	10	N/A	N/A	N/A	3+	90%	270	N/A	N/A	N/A
14	3+	90%	270	1+	10%	10	1+	80%	80	2+	90%	180	0	0	0	1+	95%	95
15	3+	90%	270	0	0	0	2+	95%	190	0	0	0	0	0	0	0	0	0
16	3+	95%	285	3+	90%	270	2+	95%	190	0	0	0	1+	95%	95	1+	95%	95
17	3+	50%	150	2+	50%	100	1+	95%	190	0	0	0	1+	95%	95	1+	95%	95
18	3+	95%	285	0	0	0	2+	55%	110	0	0	0	1+	95%	95	1+	90%	90
19	3+	75%	225	1+	10%	10	3+	70%	210	2+	10%	20	1+	95%	95	1+	95%	95
20	3+	90	270	3+	70%	210	3+	80%	240	3+	95%	285	3+	100%	300	3+	100%	300

Patients 5 and 13 had no residual disease at surgery. pHER2, phospho human epidermal growth factor receptor 2pERK1, phosphor extracellular-regulated kinase 1; N/A, not available.

ISSN: 1465-542X